Global Anti TIGIT Antibody Report 2022: Featuring Agenus, AstraZeneca, Bristol Myers and Merck Among Others – ResearchAndMarkets.com

Global Anti TIGIT Antibody Report 2022: Featuring Agenus, AstraZeneca, Bristol Myers and Merck Among Others – ResearchAndMarkets.com




Global Anti TIGIT Antibody Report 2022: Featuring Agenus, AstraZeneca, Bristol Myers and Merck Among Others – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Anti TIGIT Antibody Clinical Trials & Companies Insight 2023” report has been added to ResearchAndMarkets.com’s offering.

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of individual therapies. In addition to other elements, the study includes a detailed assessment of the current market landscape, providing information about the product’s mechanism of action, dosage and administration, and other development activities.

Companies Mentioned

  • Arcus Biosciences
  • Agenus
  • Astellas Pharma
  • AstraZeneca
  • BeiGene
  • Bristol Myers Squibb
  • Compugen
  • Gilead Sciences
  • iTeos Therapeutics
  • Merck
  • Roche
  • Seagen
  • Shanghai Henlius Biotech

Report Highlights:

  • Global Anti-TIGIT Antibodies Market Dynamics
  • Insight On Anti TIGIT Antibodies Clinical Trials Insight By Phase, Company, Country, Indication
  • Anti-TIGIT Antibodies In Clinical Trials : > 45
  • Overview Of Partnerships and Collaborations In The Global Anti-TIGIT Antibodies Market
  • Global Anti-TIGIT Antibodies Market Outlook
  • Competitive Landscape

The advancement in the field of genomics has led to the identification of T-cell immunoreceptors with immunoglobulin and ITIM domain (TIGIT) as a promising emerging immune checkpoint target. TIGIT indirectly suppresses T-cell activation and is expressed in multiple types of immune cells, including regulatory T (Treg) cells, activated T cells, and natural killer (NK) cells.

TIGIT is upregulated in T cells and NK cells after ligand binding, inhibiting these cells’ ability to kill tumor cells. Increased TIGIT expression s also associated with advanced disease and poor survival outcomes. Additionally, increased TIGIT expression after treatment is associated with disease recurrence.

Since its identification as a potential immunotherapy target, pharmaceutical companies have developed a robust pipeline of TIGIT inhibitors and are reporting promising preclinical and clinical trial results. Recently, iTeos Therapeutics has announced promising preclinical and clinical analyses supporting the multifaceted mechanism of action of its anti-TIGIT antibody, EOS-448/GSK4428859A, which is being developed in collaboration with GlaxoSmithKline. Various combinations of anti-TIGIT antibody isotopes have been studied in cancer models of mice.

Depending on the isotope used, the preclinical analyses of these combinations have demonstrated different anti-tumor activities. Strong anti-tumor activities have been found while using the isotope engaging the Fcandgamma; R, which has been linked to the activation of effector CD8 T cells and the reduction in the number of Treg cells in the tumor microenvironment. EOS-448 has further been shown to induce the depletion of the precursors of exhausted T cells in addition to regulatory T cells, but not of stem-like memory T cells.

Recent years have seen an increase in collaborations and partnerships between companies for the faster development of novel drugs. Shanghai Junshi Biosciences and Coherus Bioscience recently announced that the two are taking their immuno-oncology collaboration agreement further by allowing Coherus to initiate its option to license the former’s potential anti-TIGIT antibody – JS 006 – in the US and China.

Regulatory bodies of the two regions have already approved the drug’s Investigational new drug (IND) applications, allowing the companies to develop it further clinically. Apart from this, clinical trials are ongoing which are assessing the drug’s safety, pharmacokinetic properties, and tolerability post-dose escalation and expansion, as a monotherapy and in combination with toripalimab, an anti-PD-1 antibody, in patients with advanced solid tumors.

Apart from these trends in the market, the pipeline of novel TIGIT inhibitor is highly crowded which suggests a promising future of the market. The key drugs in research and development include including AB 154, Ociperlimab, COM902, EOS448, Tiragolumab, and others.

As per our analysis, TIGIT inhibitor is expected to enter the market by 2024, which will transform the overall immunotherapy market during the forecast period. However, the market will mainly be restricted by the long duration of drug development and stringent regulatory guidelines. However, as the healthcare sector of the majority of regions is shifting towards novel therapeutic approaches drug regulatory bodies are providing special provisions and rapid approvals are expected in coming years.

Key Topics Covered:

1. Introduction to TIGIT Inhibitor

2. Role Of TIGIT Inhibitors By Indications

3. Mechanism of Anti TIGIT Antibodies

4. Partnerships and Collaborations In The Global Anti TIGIT Antibodies Market

5. Global TIGIT inhibitors Clinical Trials Overview

6. Global Anti TIGIT Antibody Clinical Pipeline By Company, Indication and Phase

7. FDA Orphan Designation for Tiragolumab

8. Global Anti TIGIT Antibody Market Dynamics

9. Global TIGIT Inhibitor Market Future Outlook

10. Competitive Landscape

For more information about this report visit https://www.researchandmarkets.com/r/jghmkx

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900